Opinion

Podcast

Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Author(s):

Lauren Miller, MPAS, PA-C,Jayme M Heim, MSN, FNP-BC

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Videos
Gregory Mattingly, MD I St. Charles Psychiatric Associates
Duloxetine for Patients with COPD Suffering from Comorbid Depression
Enhancing Standards for Ethical Responsibilities within Clinical Research
Related Content
Cost-Related Non-Adherence Declines for Asthma, More Action Needed
January 24th 2025

Cost-Related Non-Adherence Declines for Asthma, More Action Needed

Victoria Johnson
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics| Image Credit: HCPLive
January 23rd 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Greta Bushnell, PhD, MSPH I Credit: Rutgers, School of Public Health
January 23rd 2025

Sedative, Hypnotic, Anxiolytic Use Disorders Rose from 2001 to 2019 in Young Adults

Chelsie Derman
Default thumbnail for The Medical Sisterhood podcast
January 16th 2025

Medical Sisterhood: Polished and Powerful—Women Leading the Charge in Advocacy

Mona Shahriari, MD, FAAD Shadi Kourosh, MD, MPH
Positive Results Observed with Baricitinib, Phototherapy for Severe Vitiligo
January 23rd 2025

Positive Results Observed with Baricitinib, Phototherapy for Severe Vitiligo

Tim Smith
FDA black and white logo | Credit: US Food and Drug Administration
January 23rd 2025

FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D

Abigail Brooks, MA
© 2025 MJH Life Sciences

All rights reserved.